Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1697-1708

  Tang, Jian Zhong ^a   Kong, Xiang Jun ^c   Kang, Jian ^a   Fielder, Graeme C ^a   Steiner, Michael ^a   Perry, Jo K ^a   Wu, Zheng Sheng ^d   Yin, Zhinan ^e   Zhu, Tao ^c   Liu, Dong Xu ^a   Lobie, Peter E ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; POLYCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN GFRA1; PROTEIN GFRA2; PROTEIN GFRA3; PROTEIN RET; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN; DISEASE PROGRESSION; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LAMININ; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953432090     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1077     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
2. Wilck EJ. Computed tomography screening for lung cancer. Ann Thorac Surg 2008;85:S699-700.
3. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009;6:259-65.
4. Chang APP, Thongprasert S, Tan EH, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55. (Pubitemid 47181391)
5. Clark GM ZD, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-94.
6. Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer 2009;33:73-111.
7. Airaksinen MS, Titievsky A, Saarma M. GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci 1999;13:313-25.
8. Kang J, Perry JK, Pandey V, et al. Artemin is oncogenic for human mammary carcinoma cells. Oncogene 2009;28:2034-45.
9. Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 2002;3:383-94. (Pubitemid 135706635)
10. Paratcha G, Ledda F. GDNF and GFRα: a versatile molecular complex for developing neurons. Trends Neurosci 2008;31:384-91.
11. Ceyhan GO, Giese NA, Erkan M, et al. The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 2006;244:274-81. (Pubitemid 44305543)
12. Pandey V, Qian PX, Kang J, et al. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology 2010;151:909-20.
13. Kang J, Qian PX, Pandey V, et al. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 2010 Mar 22. [Epub ahead of print].
14. Hitoshi F, Yuji O, Hirozumi S, et al. The role of glial cell line-derived neurotrophic factor (GDNF) and integrins for invasion and metastasis in human pancreatic cancer cells. J Surg Oncol 2005;91:77-83.
15. Real PJ, Cao Y, Wang R, et al. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2. Cancer Res 2004;64:7947-53. (Pubitemid 39446928)
16. Liu DX, Lobie PE. Transcriptional activation of p53 by Pitx1. Cell Death Differ 2007;14:1893-907.
17. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci U S A 2004;101:15166-71. (Pubitemid 39391736)
18. Zhu T, Starling-Emerald B, Zhang X, et al. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res 2005;65:317-24. (Pubitemid 40070824)
19. Dawson CW, Young LS. In vitro assays to study epithelial cell growth. Methods Mol Biol 2001;174:165-72.
20. Ozpolat B, Akar U, Steiner M, et al. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res 2007;5:95-108. (Pubitemid 46246770)
21. Pandey V, Perry JK, Mohankumar KM, et al. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 2008;149:3909-19.
22. Wood TJ, Sliva D, Lobie PE, et al. Specificity of transcription enhancement via the STAT responsive element in the serine protease inhibitor 2.1 promoter. Mol Cell Endocrinol 1997;130:69-81.
23. http://www.oncomine.org.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
25. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
26. Jakowlew S. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57.
27. Wang M, Atayar C, Rosati S, Bosga-Bouwer A, Kluin P, Visser L. JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 2009;218:95-103.
28. Wu M, Min C, Wang X, et al. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 2007;67:6278-85. (Pubitemid 47037510)
29. Naveilhan P, Baudet C, Mikaels A, Shen L, Westphal H, Ernfors P. Expression and regulation of GFRα3, a glial cell line-derived neurotrophic factor family receptor. Proc Natl Acad Sci U S A 1998;95:1295-300. (Pubitemid 28124952)
30. Yang C, Hutto D, Sah DW. Distribution of GDNF family receptor α3 and RET in rat and human non-neural tissues. J Mol Histol 2006;37:69-77. (Pubitemid 44421095)
31. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
32. Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol 2007;25:561-70. (Pubitemid 350002964)
33. Pelosi G, Sonzogni A, De Pas T, et al. Pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol 2010;18:103-20.
34. Ito K, Oizumi S, Fukumoto S, et al. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer 2010;68:204-10.
35. Levy L, Hill CS. Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58. (Pubitemid 43117515)
36. Zhu T, Goh EL, Graichen R, Ling L, Lobie PE. Signal transduction via the growth hormone receptor. Cell Signal 2001;13:599-616. (Pubitemid 32734097)
37. Sjostrand D, Carlsson J, Paratcha G, Persson B, Ibanez CF. Disruption of the GDNF binding site in NCAM dissociates ligand binding and homophilic cell adhesion. J Biol Chem 2007;282:12734-40. (Pubitemid 47100633)
38. Cabrera JR, Sanchez-Pulido L, Rojas AM, et al. Gas1 is related to the glial cell-derived neurotrophic factor family receptors α and regulates Ret signaling. J Biol Chem 2006;281:14330-9. (Pubitemid 43848362)
39. Trupp M, Scott R, Whittemore SR, Ibanez CF. Ret-dependent and -independent mechanisms of glial cell line-derived neurotrophic factor signaling in neuronal cells. J Biol Chem 1999;274:20885-94. (Pubitemid 129519586)
40. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006;43:1-67. (Pubitemid 43379211)
41. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ 2006;13:1351-9. (Pubitemid 44057470)
42. Gregorc V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2003;39:41-8.
43. Ludovini V, Gregorc V, Pistola L, et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2004;46:77-85.
44. Tas F, Duranyildiz D, Oguz H, et al. The value of serum Bcl-2 levels in advanced lung cancer patients. Med Oncol 2005;22:139-43.
45. Toshiyuki H, Shigeaki O, Koichi Y, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci 2003;94:394-9.
46. Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 2004;3:327-34.
47. Marinov M, Ziogas A, Pardo OE, et al. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell Lung cancer cells to RAD001. Clin Cancer Res 2009;15:1277-87.
48. Yang T-M, Barbone D, Fennell DA, Broaddus VC. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Am J Respir Cell Mol Biol 2009;41:14-23.
49. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
50. Cragg MS, Kuroda J, Puthalakath H, Huang DCS, Strasser A. Gefitinib-induced killing of NSCLC Cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:e316.
51. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.